[1]
Marco Cascella. Michael Rajnik, Arturo Cuomo, Scott C Dulebohn, Napoli RD Features, evaluation and treatment coronavirus (COVID-19). Treasure Island, FL: StatPearls Publishing 2010.
[2]
Satyam R, Bhardwaj T, Goel S, et al. miRNAs in SARS-CoV 2: A spoke in the wheel of pathogenesis. Curr Pharm Des 2021; 27: 1628-41.
[3]
Darenskaya M, Kolesnikova L, Kolesnikov S. The association of respiratory viruses with oxidative stress and antioxidants. Implications for the COVID-19 pandemic. Curr Pharm Des 2021; 27: 1618-27.
[4]
Torabi-Rahvar M, Rezaei N. Storm at the time of corona: A glimpse at the current understanding and therapeutic opportunities of the SARS-CoV-2 cytokine storm. Curr Pharm Des 2021; 27: 1549-52.
[5]
Alshammary F, Siddiqui AA, Amin J, et al. Prevention knowledge and its practice towards COVID-19 among general population of Saudi Arabia: A gender-based perspective. Curr Pharm Des 2021; 27: 1642-8.
[6]
Tavakol S, Alavijeh MS, Seifalian AM. COVID-19 vaccines in clinical trials and their mode of action for immunity against the Virus. Curr Pharm Des 2021; 27: 1553-63.
[7]
Raiteri A, Piscaglia F, Granito A, Tovoli F. Tocilizumab: From rheumatic diseases to Covid-19. Curr Pharm Des 2021; 27: 1597-607.
[8]
Tian C, Xiang M. Therapeutic agents against COVID-19 with clinical evidence. Curr Pharm Des 2021; 27: 1608-17.
[9]
Shoaib A, Azmi L, Shukla I, Alqahtani SS, Alsarra IA, Shakeel F. Properties of ethnomedicinal plants and their bioactive compounds: possible use for COVID-19 prevention and treatment. Curr Pharm Des 2021; 27: 1579-87.